

08/105444

Abstract

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the
5 group consisting of

at least one antigen overrepresented in the prostate gland or an immunologically effective portion thereof;

an expression system capable of generating *in*
10 *situ* said antigen or portion; and

an antiidiotypic antibody or fragment thereof
which mimics said antigen or portion.